The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. In this report, we discuss how current therapies are differentiated based on their performance on key drug attributes and measure the impact of these attributes on cardiologists’ prescribing behavior. We also discuss the most important unmet needs in the treatment of AHF; according to physicians surveyed, the most important unmet need is reducing AHF patients’ mortality rate. Understanding the importance of these unmet needs helps identify the most attractive opportunities in AHF treatment. We then consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the trade-offs in key attributes, such as rate of mortality, rehospitalization, and price, that surveyed physicians are willing to make when considering new treatment options for AHF.
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in January 2017.
Key companies:Bristol-Myers Squibb, Cardiorentis, Janssen, Novartis
Key drugs: inotropic sympathomimetics, loop diuretics, Natrecor, nitrate vasodilators, PDE3 inhibitors, serelaxin